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Molecularly targeted agents are changing the therapeutic landscape in advanced non-small
cell lung cancer. Since the discovery of sensitizing mutations in the epidermal growth factor
receptor (EGFR) and anaplastic lymphoma kinase (ALK) domain, clinical investigations have
focused on optimizing the efficacy of EGFR and ALK tyrosine kinase inhibitors by addressing
therapeutic resistance that commonly develops within a year of treatment initiation. Here,
we review the clinical trials of novel therapies and combination regimens that have been
undertaken in response to our evolving understanding of the mechanisms of resistance
to targeted therapy. The aim of these trials was to enhance the therapeutic efficacy of tar-
geted therapies by improving blockade and/or inhibiting parallel or compensatory signaling
pathways.We have documented the sequential conduct of EGFR and ALK biomarker-driven
trials in order to highlight particular pitfalls and successes, which should be considered in
the design of future trials. Although there remain significant challenges, substantial gains
have been made in our understanding of cellular resistance. This knowledge will drive the
design of future trials to the benefit of lung cancer patients.
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Lung cancer is the leading cause of cancer related deaths worldwide
(1). Non-small cell lung cancer (NSCLC) represents approximately
85% of all lung cancers (2). In the advanced disease setting,
systemic platinum-based chemotherapy yields survival rates of
approximately 1 year (3). In the last decade, the targeted inhibition
of oncogenic driver mutations with molecular therapies of which
the epidermal growth factor receptor (EGFR) and the anaplastic
lymphoma kinase (ALK) are the most studied targets, has seen
dramatic improvements in overall survival in defined subsets of
patients (4, 5). However, despite impressive early response rates,
most patients progress within a year (4). Herein, we review clinical
trials undertaken in response to our evolving understanding of the
oncogenic drivers and molecular mechanisms of drug resistance.
BACKGROUND
Given its important role in tumor growth and proliferation, the
EGFR pathway has been the focus of intense clinical investigation
across many tumor sites (6, 7). The high protein expression levels
observed in NSCLC across all histologies (8), particularly among
those with advanced disease (9), provided the initial impetus for
the early lung cancer trials targeting the EGFR pathway by small
molecule tyrosine kinase inhibitors (EGFR-TKIs) and anti-EGFR
monoclonal antibodies.
Early trials in advanced NSCLC evaluated EGFR-TKIs as both
monotherapy after chemotherapy failure and in combination
with chemotherapy in the first-line setting. As a monotherapy,
the EGFR-TKI erlotinib, was shown to improve progression free
survival (PFS) (2.2 vs. 1.8 months, p< 0.001) and overall sur-
vival (OS) over best supportive care (6.7 vs. 4.7, p< 0.001) in
unselected NSCLC patients with advanced disease who had failed
one or two prior lines of chemotherapy (BR 21) (10). Although
gefitinib, another EGFR-TKI, was similarly able to delay disease
progression over placebo in the second/third-line setting (3.0
vs. 2.6 months, p= 0.0006), the lack of overall survival benefit
(5.6 vs. 5.1 months, p= 0.087) in the definitive phase III trial
(ISEL) (11)resulted in the withdrawal of gefitinib’s accelerated
FDA approval, which was based on encouraging phase II data
(IDEAL-1, IDEAL-2) (12, 13). Disappointingly, when used in
combination with upfront chemotherapy in unselected patients
with advanced NSCLC, neither erlotinib nor gefitinib was shown
to improve overall survival (14–17). The strategy of combining
EGFR-TKIs and chemotherapy, therefore, has since largely been
abandoned.
Objective responses in most of the early EGFR-TKI trials in
unselected patients was quite variable, with many trials indepen-
dently identifying a small subgroup of extreme responders (10,
11), against a large background of patients with primary resis-
tance to EGFR inhibition. In these trials, the extreme responders
were most commonly defined by their clinical and ethnic char-
acteristics (Asian, non-smokers) and not by their pre-treatment
EGFR protein expression levels. With the discovery of the acti-
vating EGFR mutations in exon 19 and 21 of the kinase domain
(18, 19), came a number of retrospective mutational studies of
the earlier anti-EGFR trials, which confirmed the importance
of these mutations (20, 21). These studies lead to the molec-
ular characterization of EGFR-TKI responders and the subse-
quent EGFR mutation-positive biomarker-driven trials, detailed
below.
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PAST CLINICAL TRIALS ADDRESSING RESISTANCE
The restriction of EGFR-TKI trials to patients whose tumors har-
bored activating EGFR mutations represented the first attempt to
address primary drug resistance, by limiting exposure in patients
unlikely to benefit from EGFR-TKIs. Six large randomized phase
III trials that enriched or selectively enrolled patients with acti-
vating EGFR mutations definitively confirmed the benefit of first-
generation reversible EGFR-TKIs over standard chemotherapy in
the first-line setting (Table 1) (22–27). These trials, which collec-
tively enrolled over 2200 patients, showed a doubling of response
rate to 60–80% over chemotherapy alone in patients whose tumors
harbored the EGFR mutation (22–27). In the four trials that
only enrolled EGFR-mutant positive NSCLC patients (two gefi-
tinib, two erlonitib), EGFR-TKIs were shown to extend PFS by
3–8 months (24–27). Consequently, targeted monotherapy with
erlotinib or gefitinib has now become standard of care in the
first-line setting in patients with EGFR mutation-positive tumors.
Due to their different mechanism of action, anti-EGFR mono-
clonal antibodies have also been evaluated in the management of
advanced NSCLC. The most well studied of these agents is cetux-
imab, a monoclonal chimeric IgG1 antibody, that inhibits EGFR
pathway activation by binding to the EGF receptor (28). Unlike
its small molecule counterpart, monotherapy trials of cetuximab
were disappointing in advanced NSCLC (29). However, cetuximab
has been successfully combined with chemotherapy in the first-
line setting. In a large phase III trial that enrolled 1125 patients
with advanced NSCLC (FLEX) (30), cetuximab was shown to
improve overall survival (11.3 vs. 10.1 months, p= 0.004) when
combined with cisplatin and vinorelbine, with greater efficacy
noted in patients with higher EGFR protein expression (31).
While a similar smaller study (n= 676) of cetuximab with a car-
boplatin/paclitaxel regimen (BMS099) (32) did not demonstrate
improved PFS or OS with the addition of cetuximab, a meta-
analysis of four randomized phase II&III trials (which included
the BMS099 study results) did show that cetuximab with first-line
Table 1 | Randomized phase III trials of first-generation EGFR-TKIs in
EGFR mutation (+)/enriched populations.
Study Agent EGFR+/N PFS (EGFR+)
(months)
OS (EGFR+)
(months)
NEJ002 (24) Gefitinib 224/224 10.8 vs. 5.4
(HR 0.3)
27.7 vs. 26.6
(HR 0.89)
WJTOG-3405
(25)
Gefitinib 192/192 9.2 vs. 6.3
(HR 0.5)
36 vs. 39
(HR 1.19)
OPTIMAL
(26)
Erlotinib 154/154 13.1 vs. 4.6
HR 0.16
HR 1.065
EURTAC (27) Erlotinib 153/153 9.7 vs. 5.2
HR 0.37
19.3 vs. 19.5
HR 1.04
IPASS (22) Gefitinib 261/1217 9.5 vs. 6.3
HR 0.48
21.6 vs. 21.9
HR 1.0
SIGNAL (23) Gefitinib 42/309 8.0 vs. 6.3
HR 0.54
27.2 vs. 25.6
HR 1.04
platinum-based chemotherapy improved both PFS and OS (33).
Cetuximab’s inconsistent and limited clinical efficacy, however,
has restricted the uptake and regulatory approval of this anti-
EGFR monoclonal antibody in advanced NSCLC. While other
anti-EGFR monoclonal IgG1 antibodies, such as matuzumab, have
demonstrated some efficacy in combination with chemotherapy
in the second-line setting in phase II trials (34), other anti-EGFR
monoclonal IgG2 antibodies (e.g., panitumumab) in combination
with chemotherapy have shown little activity, even in patients with
EGFR-mutant disease (35). Newer fully human recombinant anti-
EGFR IgG1 monoclonal antibodies (e.g., necitumumab), which
lack the immunoreactivity of earlier chimeric (human/mouse)
monoclonal antibodies, are currently under investigation in cer-
tain histological subgroups in combination with chemotherapy, as
detailed below.
As noted previously, even in the presence of sensitizing EGFR
mutations, only 60–80% of patients with advanced NSCLC
respond to EGFR-TKIs. Despite earlier failed attempts to com-
bine EGFR-TKIs with chemotherapy, other combination regimens
were evaluated early in the clinical development of EGFR-TKIs, in
an attempt to expand and enhance their therapeutic efficacy. To
understand the rationale for these, and other combination regi-
mens evaluated in molecular oncology clinical trials, it is useful to
consider the therapeutic strategies advanced by Dancey and col-
leagues (36) to address targeted therapy drug resistance, namely
to (1) augment the first agent’s activity; (2) enhance single target
blockade; (3) inhibit multiple targets or multiple pathways; and
(4) inhibit compensatory pathways. While combination therapies
with chemotherapy used the first of these strategies, strategies two
to four have guided most clinical research in the acquired resistance
setting, as detailed below.
PAST TRIALS OF COMBINATION THERAPIES
Dual targeting of a single receptor was the rationale behind the
early trials of combined EGFR-TKI and anti-EGFR monoclonal
antibody therapies, which, due to the off-target effects of the first-
generation EGFR-TKIs, proved very toxic (37). Multiple pathway
inhibition was the guiding strategy behind combining EGFR-
TKIs with the anti-VEGF monoclonal antibody, bevacizumab,
given its earlier success in improving overall survival in advanced
NSCLC when given with chemotherapy (38). Although early tri-
als of dual VEGF and EGFR inhibition were encouraging (39,
40), more recent trials in unselected populations of VEGF/EGFR
inhibitors, such as vandetanib, do not support this approach in the
management of advanced NSCLC (41).
CURRENT CLINICAL TRIALS ADDRESSING RESISTANCE
Despite dramatic responses in patients whose tumors harbor
EGFR activating mutations, most patients become resistant to
EGFR-TKIs within the first year (10, 11). The majority of cur-
rent trials are, therefore, focused on addressing the mechanisms of
acquired resistance (Table 2). The most common of these mech-
anisms is the development of a second mutation of the EGFR,
namely the T790M mutation (T790M), which occurs in up to 60%
of those with EGFR-TKI resistant disease (42). The newer second-
generation pan-HER irreversible inhibitors provide compensatory
pathway inhibition by direct targeting of the resistant T790M
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Table 2 | Select trials addressing acquired resistance to targeted therapy.
Line of therapy Agents Trial PFS (months)
MONOTHERAPYTRIALSTARGETINGTHE EGFR DOMAIN
First line Afatinib vs. pem/cispl LuxLung 3 (45) 11.1 vs. 6.9 (p=0.001)
First line Afatinib vs. gem/cispl LuxLung 6 (46) 11.0 vs. 5.6 (p<0.0001)
First line Dacomitinib vs. gefitinib ARCHER 1050 Results pending
Second line Afatinib vs. placebo LuxLung 1 (43) 3.3 vs. 1.1 (p<0.0001)
Second line Dacomitinib vs. placebo BR 26 (44) 2.7 vs. 1.4 (p<0.0001)
COMBINATIONTHERAPIESTARGETINGTHE MET COMPENSATORY PATHWAY
Second/third line Tivantinib+erlotinib vs. erlotinib+placebo Marqueea (47) 3.6 vs. 1.9 (p<0.0001)
Second/third line Onartuzumab+erlotinib vs. erlotinib+placebo METLunga (48) 2.7 vs. 2.6 (p=0.92)
aTrial stopped early for futility to meet primary endpoint.
mutation and bind irreversibly to 2 or more receptors of the EGFR
domain, thus providing enhanced EGFR pathway blockade. Of
the second-generation inhibitors, afatinib and dacomitinib have
been the most extensively studied, in both heavily pre-treated
patients and in the first-line setting. Afatinib has been evalu-
ated in an EGFR-mutant enriched population who had failed
one to two lines of chemotherapy and an EGFR-TKI (LUX-Lung
1) (43). In this placebo-controlled phase III trial, afatinib was
shown to improve PFS (3.3 vs. 1.1 months, p< 0.0001) but not
overall survival (10.8 vs. 12.0 months, p= 0.87) (43). A similar
study was also undertaken with dacomitinib (BR. 26) (44) in
patients who had failed one to three lines of chemotherapy and an
EGFR-TKI. As with afatinib, dacomitinib showed improved PFS
(2.7 vs. 1.4 months, p< 0.0001) but did not improve OS (6.8 vs.
6.3 months, p= 0.099) (44).
Unlike the disappointing results observed in the second/third-
line setting, second-generation EGFR inhibitors have proven effec-
tive in the first-line setting in patients whose tumors harbor
EGFR activating mutations. Specifically, afatinib has been shown
to improve PFS compared to pemetrexed/cisplatin (LUX-Lung 3)
(11.1 vs. 6.9 months, p= 0.001) (45) and, more recently, com-
pared to gemcitabine/cisplatin (LUX-Lung 6) (11.0 vs. 5.6 months,
p< 0.0001) (46). Dacomitinib is also being evaluated in a head-
to-head phase III trial against gefitinib (ARCHER 1050), with the
results expected next year (www.clinicaltrials.gov: NCT01774721).
In the context of acquired resistance to anti-EGFR therapies, the
activation of alternate signaling pathways by both adaptive muta-
tions that develop outside the EGFR kinase domain and mutation-
independent factors have also been described (49), and are inform-
ing novel combination therapies to address these acquired mech-
anisms of resistance. The most common of these alterations is
MET activation, which occurs in up to 20% of patients with
acquired resistance (50). Both small molecule inhibitors targeting
MET and anti-MET monoclonal antibodies have been combined
with first-generation EGFR-TKIs. The small molecule, tivantinib,
and the monoclonal antibody onartuzumab have both been eval-
uated in the second-line setting in EGFR-TKI naïve patients after
chemotherapy failure. In phase II trials, patients were screened
and stratified by EGFR mutation status with planned subgroup
analysis by both EGFR mutation and pre-treatment tumor MET
expression levels. Despite promising phase II data in patients
whose tumors were strongly positive for MET by immunohis-
tochemistry (IHC) (51), the combination of onartuzumab and
erlotinib in the phase III trial was not shown to improve PFS
(2.7 vs. 2.6 months, p= 0.92) or objective response rate (ORR)
(8.4 vs. 9.6%, p= 0.63) and was stopped early for futility to meet
its primary endpoint of improved OS (48). The small molecule
tivantinib had a similar outcome, with the phase III trial discontin-
ued prematurely for futility for the primary outcome of improved
overall survival, which at the planned interim analysis was com-
parable to EGFR monotherapy (8.5 vs. 7.8, HR= 0.98, p= 0.81)
(47). Given the failure of these phase III trials to improve sur-
vival, direct targeting of MET as a strategy to enhance EGFR-TKI
efficacy has an uncertain future.
The failure of dual MET/EGFR inhibition to improve OS in the
second-line setting can, in part, be attributed to fact that none
of these trials, which were designed to address acquired resis-
tance to EGFR-TKIs, restricted enrollment to patients with tumors
harboring EGFR activating mutations and due to the lack of a
robust biomarker predictive of efficacy to MET inhibition. The
more focused strategy applied in the first-line setting to evaluate
of the first and second-generation EGFR-TKIs, and more recently
to ALK inhibitors, which limited enrollment to EGFR mutation-
positive and ALK mutation-positive NSCLC, respectively, have
been far more successful. In the case of the ALK inhibitor, crizo-
tinib, accelerated approval was granted based on clinical activity
observed in a phase I dose-escalation and expansion study, which
screened over 1500 pre-treated patients and selectively enrolled 82
patients whose tumors screened positive for the ALK rearrange-
ment (5% prevalence) (52). Results of the definitive phase III trial
of first-line crizotinib compared to chemotherapy have recently
confirmed these initial findings (53). Using a similar approach of
selective enrollment, the second-generation ALK inhibitor cere-
tinib (LDK378) has also recently achieved regulatory FDA drug
approval in patients who have failed the crizotinib, by demonstrat-
ing antitumor activity and ORR of ~60% in a heavily pre-treated
populations in a phase I trial (ASCEND-1) (54).
THE FUTURE OF CLINICAL TRIALS OF ACQUIRED RESISTANCE
Moving forward, clinical trials of acquired resistance will continue
to focus on the testing of novel monotherapies and combination
therapies targeting the EGFR kinase domain. In the former
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case, phase III clinical trials are currently on-going compar-
ing the efficacy of the second-generation irreversible EGFR-TKIs
against the first-generation inhibitors, in the second-line setting
in advanced squamous NSCLC (LuxLung 8, afatinib vs. erlotinib,
www.clinicaltrials.gov: NCT01523587) and in the first-line treat-
ment of patients with EGFR-mutant disease (ARCHER 1050,
dacomitinib vs. gefitinib, www.clinicaltrials.gov: NCT01774721).
Disappointingly, the results of another phase III trial comparing
first and second-generation EGFR-TKIs in the second/third-line
setting (ARCHER 1009: dacomitinib vs. erlotinib) do not support
the greater clinical efficacy of the newer EGFR-TKIs in unselected
patients with advanced NSCLC (55). However, the results from
the two on-going phase III trials, mentioned above, are eagerly
awaited.
THIRD-GENERATION EGFR-TKIs AND NEWER RECOMBINANT
ANTI-EGFR MONOCLONAL ANTIBODIES
A number of third-generation EGFR-TKIs are also in develop-
ment, with AZ9291 and CO-1686 being the most advanced of
these T790M-specific small molecule inhibitors. Results of early
phase I trials of both AZ9291 and CO-1686 in EGFR mutation-
positive NSCLC patients previously treated with EGFR-TKIs are
encouraging. In both trials, which required screening biopsies
for centralized T790M mutation testing, objectives responses of
~60% in patients testing T790M positive at screening have been
observed (56, 57), with responses also noted in patients lacking the
T790M mutation receiving AZ9291, albeit less frequently (23%)
(56). Definitive phase III trials of these molecularly targeted agents
are planned.
The recent success of the newer recombinant anti-EGFR mono-
clonal antibody, necitumumab, in combination with gemcitabine–
cisplatin chemotherapy over chemotherapy alone in the first-line
treatment of patients with advanced squamous NSCLC (58) (OS:
11.5 vs. 9.9, p= 0.012) is also of interest in advanced NSCLC.
Although potentially effective in the primary resistance setting,
what role necitumumab will play in the acquired resistance setting
in patients with squamous and non-squamous NSCLC histology
remains to be determined.
DUAL TARGETING OF THE EGFR KINASE DOMAIN
Dual targeting of the EGFR kinase domain, although historically
quite toxic, will also likely continue to be explored as a strategy
to optimize EGFR-TKI therapy given the phase I dose-escalation
and expansion trial demonstrating ORR of ~30% with dual ther-
apy with the anti-EGFR monoclonal antibody cetuximab and
afatinib in patients with acquired resistance to first-generation
EGFR-TKIs (59). These encouraging results, however, are tem-
pered by the continued toxicity of this combination regimen with
77 and 69% of patients experiencing rash and diarrhea (any grade),
respectively (59).
SECOND-GENERATION ALK INHIBITORS
As secondary mutations in the ALK domain have been identified in
approximately one third of patients with acquired resistance to the
ALK inhibitor crizotinib (60), clinical trials in the ALK resistance
setting are also focused on the evaluation of more potent second-
generation molecular therapies. Of note, high response rates with
the newer second-generation ALK inhibitor, ceretinib, have been
observed in patients with and without secondary ALK mutations
(54), suggesting that their benefit in ALK-resistant disease may not
be limited to patients with secondary ALK mutations. A number
of other second-generation ALK inhibitors are also in early clini-
cal development (e.g., AP26113), with promising phase I/II results
emerging (61).
DUAL EGFR AND MET INHIBITION
While the dual inhibition of EGFR and MET-mediated pathway
inhibition by direct MET targeting has not been successful to
date, other c-MET inhibitors are being investigated (e.g., INC 280,
XL184). A related mechanism of EGFT-TKI resistance is MET acti-
vation by its ligand hepatocyte growth factor (HGF) (62) that when
overexpressed enables this compensatory mechanism of pathway
activation. Preliminary results of a phase I clinical trial evaluating
dual inhibition of EGFR and HGF with erlotinib and rilotumumab
(AMG 102), a HGF-binding monoclonal antibody, have recently
been reported (63) and a phase II study is on-going.
EGFR AND HSP 90 INHIBITORS
As a molecular chaperone for proteins involved in MET, HGF,
and EML4/ALK fusion, the inhibition of heat shock protein 90
(HSP90) is also being considered as a target for compensatory
pathway inhibition and has fueled combination therapies in both
EGFR-TKI and ALK inhibitor-resistant disease. In the advanced
NSCLC EGFR-TKI resistant setting, the HSP90 small molecule
inhibitor AUY922 is being evaluated as monotherapy in a phase
II clinical trial vs. pemetrexed or docetaxel in patients with
tumors with activating EGFR mutations (www.clinicaltrials.gov:
NCT016461250). This agent is also being assessed in a phase
II trial in patients with de novo resistant T790M mutations
not previously treated with EGFR-TKIs (www.clinicaltrials.gov:
NCT01854034) and in patients with EGFR mutations and/or
EGFR-TKI resistant disease, as part of a phase II cluster study
in Chinese patients evaluating five novel inhibitors of HSP90,
PI3K, ALK, MET, and MEK (64). Further, AUY922 is also being
assessed in combination with erlotinib in patients who have previ-
ously responded to EGFR-TKIs and/or whose tumors harbor acti-
vating EGFR mutations (www.clinicaltrials.gov: NCT01259089),
with results expected in the near future. The safety and activ-
ity of another HSP90 inhibitor, ganetespib (STA-9090), has also
been assessed in a heavily pre-treated population with NSCLC in
a phase II single arm trial with three cohorts (EGFR+, KRAS+,
EGFR/KRAS wild-type) (65). In this study, partial responses were
noted in 4/66 patients in the EGFR/KRAS wild-type cohort, all
of whom were retrospectively confirmed to have disease that har-
bored the ALK gene rearrangement (65). Despite interest in this
HSP90 inhibitor in combination with chemotherapy (GALAXY-
1, GALAXY-2) (66, 67), ganetespib’s role in inhibiting EGFR
is unclear. Given encouraging preclinical data in ALK-driven
tumors resistant to crizotinib (68), ganetespib is being inves-
tigated in clinical trials in NSCLC patients with ALK-driven
tumors, as a monotherapy in heavily treated (crizotinib naïve)
patients (www.clinicaltrials.gov: NCT01562015) and in combina-
tion with crizotinib in patients with prior exposure to crizotinib
(www.clinicaltrials.gov: NCT01579994).
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CONCLUSION
Over the last decade, our understanding of the EGF receptor
and our ability to target it has evolved significantly, from single
receptor first-generation inhibitors in unselected populations to
biomarker-driven clinical trials of more potent second and third-
generation irreversible multi-targeted EGFR-TKIs and humanized
monoclonal antibodies. The failure of earlier trials targeting the
EGF receptor was in part due to the lack of good predictive
biomarkers of efficacy. The future success of targeted strategies
addressing resistance will hinge on our ability to identify these
biomarkers and selectively enroll patients to clinical trials, a strat-
egy that has been more successfully applied in the approval of ALK
inhibitors. Furthermore, in order to be successful in the acquired
resistance setting, rebiopsy, and tailored mechanism-driven strate-
gies will be required at the time of progression, with a concurrent
reduction in the toxicity of multi-targeted and combination ther-
apies. Importantly, the knowledge gained from investigations of
EGFR and ALK inhibition over the last decade can be applied to
the testing of novel therapies targeting newly discovered onco-
genic drivers in NSCLC (69) in order to optimize study designs
and streamline regulatory approval, to the benefit of all patients
with NSCLC.
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